Vista Pharmaceuticals Limited (BOM: 524711)
India
· Delayed Price · Currency is INR 11.57
-0.11 (-0.94%)
At close: Dec 27, 2024
Vista Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Operating Revenue | 91.27 | 102.88 | 10.04 | 3.95 | 12.66 | 227.59 | Upgrade
|
| Other Revenue | - | -0 | - | -0 | - | - | Upgrade
|
| Revenue | 91.27 | 102.88 | 10.04 | 3.95 | 12.66 | 227.59 | Upgrade
|
| Revenue Growth (YoY) | 41.40% | 924.98% | 154.42% | -68.85% | -94.44% | -26.76% | Upgrade
|
| Cost of Revenue | 72.65 | 92.86 | 28.61 | 3.9 | 8.47 | 240.65 | Upgrade
|
| Gross Profit | 18.61 | 10.02 | -18.57 | 0.05 | 4.2 | -13.06 | Upgrade
|
| Selling, General & Admin | 20.83 | 20.17 | 5.34 | 7.17 | 12.11 | 15.88 | Upgrade
|
| Other Operating Expenses | 27.19 | 21.71 | 14.93 | 4.99 | 9.39 | 19.04 | Upgrade
|
| Operating Expenses | 55.32 | 49.07 | 26.44 | 18.32 | 28.77 | 48.38 | Upgrade
|
| Operating Income | -36.71 | -39.05 | -45.01 | -18.27 | -24.57 | -61.44 | Upgrade
|
| Interest Expense | -11.24 | -12.34 | -13.1 | -8.98 | -15.45 | -13.64 | Upgrade
|
| Interest & Investment Income | 1.45 | 1.45 | 1.29 | 1.66 | 1 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.69 | -0.69 | -1.63 | -0.57 | - | 1.58 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.1 | 1.43 | -0.31 | -0.02 | 0.91 | 34.14 | Upgrade
|
| EBT Excluding Unusual Items | -47.1 | -49.21 | -58.76 | -26.18 | -38.11 | -39.36 | Upgrade
|
| Other Unusual Items | -0.13 | -2.57 | - | - | - | - | Upgrade
|
| Pretax Income | -47.23 | -51.77 | -58.76 | -26.18 | -38.11 | -39.36 | Upgrade
|
| Income Tax Expense | -13.54 | -6.65 | -2.14 | -17.29 | -18.03 | -2.59 | Upgrade
|
| Net Income | -33.69 | -45.12 | -56.62 | -8.89 | -20.09 | -36.77 | Upgrade
|
| Net Income to Common | -33.69 | -45.12 | -56.62 | -8.89 | -20.09 | -36.77 | Upgrade
|
| Shares Outstanding (Basic) | 53 | 44 | 37 | 37 | 35 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 53 | 44 | 37 | 37 | 35 | 30 | Upgrade
|
| Shares Change (YoY) | 24.76% | 18.55% | 0.11% | 6.18% | 14.11% | -1.69% | Upgrade
|
| EPS (Basic) | -0.64 | -1.03 | -1.54 | -0.24 | -0.58 | -1.21 | Upgrade
|
| EPS (Diluted) | -0.64 | -1.03 | -1.54 | -0.24 | -0.58 | -1.22 | Upgrade
|
| Free Cash Flow | -76.43 | -57.04 | -29.82 | -10.07 | -70.46 | 5.58 | Upgrade
|
| Free Cash Flow Per Share | -1.45 | -1.31 | -0.81 | -0.27 | -2.03 | 0.18 | Upgrade
|
| Gross Margin | 20.39% | 9.74% | -185.01% | 1.22% | 33.14% | -5.74% | Upgrade
|
| Operating Margin | -40.23% | -37.96% | -448.47% | -463.07% | -194.04% | -26.99% | Upgrade
|
| Profit Margin | -36.91% | -43.86% | -564.11% | -225.25% | -158.61% | -16.16% | Upgrade
|
| Free Cash Flow Margin | -83.74% | -55.44% | -297.07% | -255.34% | -556.35% | 2.45% | Upgrade
|
| EBITDA | -29.41 | -31.86 | -38.84 | -12.11 | -17.3 | -47.97 | Upgrade
|
| EBITDA Margin | -32.22% | -30.97% | - | - | -136.58% | -21.08% | Upgrade
|
| D&A For EBITDA | 7.31 | 7.2 | 6.18 | 6.16 | 7.28 | 13.46 | Upgrade
|
| EBIT | -36.71 | -39.05 | -45.01 | -18.27 | -24.57 | -61.44 | Upgrade
|
| EBIT Margin | -40.23% | -37.96% | - | - | -194.04% | -26.99% | Upgrade
|
| Revenue as Reported | 93.27 | 106.21 | 14.03 | 5.6 | 14.61 | 265.07 | Upgrade
|
| Advertising Expenses | - | 1.14 | 0.1 | 0.66 | 0.08 | 0.03 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.